Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
73
ISIN
US8776191061
Website
TSHA Metrics
BasicAdvanced
$545M
-
-$0.33
1.02
-
Price and volume
Market cap
$545M
Beta
1.02
52-week high
$3.24
52-week low
$1.05
Average daily volume
4.1M
Financial strength
Current ratio
5.351
Quick ratio
5.169
Long term debt to equity
108.149
Total debt to equity
108.149
Interest coverage (TTM)
-909.91%
Profitability
EBITDA (TTM)
-82.509
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,201.08%
Operating margin (TTM)
-1,158.80%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-35.91%
Return on equity (TTM)
-159.34%
Valuation
Price to revenue (TTM)
91.295
Price to book
9.46
Price to tangible book (TTM)
9.46
Price to free cash flow (TTM)
-7.846
Free cash flow yield (TTM)
-12.75%
Free cash flow per share (TTM)
-32.37%
Growth
Revenue change (TTM)
-48.97%
Earnings per share change (TTM)
-55.22%
3-year earnings per share growth (CAGR)
-59.64%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
TSHA News
AllArticlesVideos
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $545M as of July 11, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of July 11, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.